Research Paper Volume 8, Issue 12 pp 3311—3320
Association between genetic variants in the XPG gene and gastric cancer risk in a Southern Chinese population
- 1 Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Department of Experimental Research, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong, China
- 2 Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China
- 3 Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China
- 4 School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China
- 5 Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China
- 6 Department of Medical Genetics, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080,Guangdong, China
- 7 Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China
Received: September 27, 2016 Accepted: November 21, 2016 Published: December 6, 2016
https://doi.org/10.18632/aging.101119How to Cite
Abstract
Xeroderma pigmentosum group G (XPG) recognizes and excises DNA damage on the 3’ side during the DNA repair process. Previous studies indicated that XPG gene polymorphisms may associate with gastric cancer susceptibility, but results were inconsistent. We evaluated the association of five potentially functional XPG polymorphisms (rs2094258 C>T, rs751402 C>T, rs2296147 T>C, rs1047768 T>C, and rs873601 G>A) with gastric cancer susceptibility in 1142 gastric cancer cases and 1173 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression models. Overall, no significant association was detected between any of selected polymorphism and gastric cancer risk. However, we found that individuals carrying 3-4 risk genotypes were at significantly higher risk of gastric cancer than those with 0-2 risk genotypes (OR=1.32, 95% CI=1.04-1.68, P=0.021). The stratification analysis revealed that the cumulative effect of risk genotypes (3-4 vs. 0-2) on gastric cancer were more prominent among subgroups older than 58 years and men. In conclusion, our results indicated that none of the selected XPG polymorphism could significantly alter gastric cancer susceptibility alone. These polymorphisms might collectively confer increased gastric cancer susceptibility. These findings would be strengthened by larger prospective multicenter studies involving different ethnic populations.
Introduction
Gastric cancer is one of the most common cancers with high mortality, ranking as the fifth most common and the third deadliest cancer in the world [1]. Decreasing trends in gastric cancer incidence and mortality have been reported in most industrialized countries, whereas it is still prevalent in developing countries, predominantly in China [2]. Despite remarkable progress achieved in multimodal therapy strategies, the survival of gastric cancer remains poor with overall 5-year survival rates hovering around 25% [3]. Helicobacter pylori (H. pylori) infection is a well-established risk factor for gastric cancer. However, some countries with a high H. pylori infection rate have disproportionately low gastric cancer incidence or mortality [4–6]. These observations suggested that rather than any single factor alone, the development of gastric cancer stem from a combination of multiple factors, such as H. pylori infection, nutritional deficiencies, a high salt or a low fiber diet, smoking, alcohol consumption, high body mass index [7,8], and genetic predisposition [9].
DNA repair system is responsible for maintaining the stability and integrity of human genomic DNA [10], and DNA repair genes may serve as potential biomarkers for cancer predication and prognosis [11]. Nucleotide excision repair (NER), one of the highly evolutionarily conserved pathway, can monitor and repair a variety of DNA damages [12,13]. Failure to repair DNA damages may lead to a number of human diseases including xeroderma pigmentosum (XP) [14]. Xeroderma pigmentosum group G (XPG) gene is one of eight key genes [XPA to XPG, and excision repair cross complementing group-1 (ERCC1)] in the NER pathway [15]. XPG can recognize and cut DNA lesion on the 3’ side to ensure the proper repair of damaged DNA [16,17]. XPG also serves as a nonenzymatic scaffolding for subsequent 5’ incision by the XPF/ERCC1 heterodimer during the NER process [18].
Thus far, a number of studies have reported the relationship between single nucleotide polymorphisms (SNPs) in the XPG gene and cancer risk, including lung cancer [19,20], gastric cancer [21–24], esophageal squamous cell carcinoma [25], colorectal cancer [26–28], and neuroblastoma [29]. However, only a few papers with small sample sizes are available regarding the role of XPG gene SNPs in gastric cancer carcinogenesis, and conclusions remain conflicting [21–24]. Therefore, we performed this study to precisely determine the association between five potentially functional SNPs (rs2094258 C>T, rs751402 C>T, rs2296147 T>C, rs1047768 T>C and rs873601G>A) in the XPG gene and gastric cancer susceptibility with a total of 1142 patients and 1173 cancer-free controls in a Southern Chinese population.
Results
Population characteristics
The final analysis consisted of 1142 cases and 1173 healthy controls (Supplemental Table S1). There were 65.59% and 67.26% men in cases and controls (P=0.393), respectively. However, regarding age, smoking status, drinking status, and pack-years, there existed significant difference (P<0.0001) between the cases and controls. Thus, we further adjusted for these variables in the multivariate analyses. Of the gastric cancer patients, 240 (21.02%) cases were diagnosed with gastric cardia adenocarcinoma, while 902 (78.98%) cases were with non-gastric cardia adenocarcinoma. In term of stage, 140 (12.26%), 329 (28.81%), 456 (39.93%), and 217 (19.00%) cases were classified as TNM stage I, II, III, and IV, respectively, according to the 7th Edition of the American Joint Committee on Cancer (AJCC) [30].
Associations between XPG gene polymorphisms and gastric cancer risk
The genotype frequencies of cases and controls for the five XPG SNPs and their associations with gastric cancer risk were summarized in Table 1. Observed genotype frequency distributions of all SNPs among the control subjects were in agreement with Hardy-Weinberg equilibrium (HWE). In the single factor analysis, no significant associations were observed between any of all the five polymorphisms and gastric cancer risk before and after adjusting for age, gender, pack-years, smoking and drinking status. We then determined the risk genotypes for each SNP based on its association with gastric cancer susceptibility. If a genotype of a SNP was associated with increase gastric cancer risk [odds ratio (OR)>1], the genotype was considered as a risk genotype, even if the association was not significant. When we combined the five polymorphisms, we observed that carriers of 3-4 risk genotypes had a significantly increased gastric cancer risk by 32%, when compared to carriers of 0-2 risk genotypes [OR=1.32, 95% confidence interval (CI)=1.04-1.68, P=0.021]. However, this association were weakened and became borderline significant (adjusted OR=1.29, 95% CI=0.99-1.69, P=0.062) after adjustment for age, gender, pack-years, smoking and drinking status.
Table 1. Logistic regression analysis of associations between XPG and gastric cancer risk.
| Genotypes | Cases (n=1142) | Controls (n=1173) | Pa | Crude OR (95% CI) | P | Adjusted OR (95% CI) b | Pb | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| rs2094258 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CC | 499 (43.70) | 527 (44.93) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CT | 508 (44.48) | 524 (44.67) | 1.02 (0.86-1.22) | 0.789 | 0.99 (0.82-1.21) | 0.938 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TT | 135 (11.82) | 122 (10.40) | 1.17 (0.89-1.54) | 0.265 | 1.17 (0.86-1.59) | 0.329 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dominant | 643 (56.30) | 646 (55.07) | 0.551 | 1.05 (0.89-1.24) | 0.551 | 1.03 (0.85-1.24) | 0.794 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additive model | 0.534 | 1.06 (0.94-1.20) | 0.338 | 1.05 (0.91-1.21) | 0.488 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recessive | 1007 (88.18) | 1051 (89.60) | 0.277 | 1.16 (0.89-1.50) | 0.277 | 1.17 (0.87-1.57) | 0.291 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| rs751402 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CC | 426 (37.30) | 433 (36.91) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CT | 555 (48.60) | 551 (46.97) | 1.02 (0.86-1.22) | 0.796 | 1.09 (0.89-1.34) | 0.397 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TT | 161 (14.10) | 189 (16.11) | 0.87 (0.68-1.11) | 0.258 | 0.87 (0.65-1.15) | 0.328 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dominant | 716 (62.70) | 740 (63.09) | 0.846 | 0.98 (0.83-1.16) | 0.846 | 1.03 (0.85-1.25) | 0.740 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additive model | 0.387 | 0.95 (0.84-1.07) | 0.401 | 0.97 (0.84-1.10) | 0.606 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recessive | 981 (85.90) | 984 (83.89) | 0.176 | 0.86 (0.68-1.07) | 0.177 | 0.83 (0.64-1.07) | 0.150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| rs2296147 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TT | 725 (63.49) | 746(63.60) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CT | 364 (31.87) | 388 (33.08) | 0.97 (0.81-1.15) | 0.694 | 0.98 (0.80-1.20) | 0.856 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CC | 53 (4.64) | 39 (3.32) | 1.40 (0.91-2.14) | 0.123 | 1.28 (0.78-2.08) | 0.329 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dominant | 417 (36.51) | 427 (36.40) | 0.955 | 1.01 (0.85-1.19) | 0.955 | 1.01 (0.83-1.22) | 0.927 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additive model | 0.249 | 1.05 (0.91-1.21) | 0.544 | 1.04 (0.88-1.22) | 0.672 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recessive | 1089 (95.36) | 1134 (96.68) | 0.105 | 1.42 (0.93-2.16) | 0.107 | 1.28 (0.79-2.09) | 0.312 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| rs1047768 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TT | 607 (53.15) | 625 (53.28) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TC | 445 (38.97) | 461 (39.30) | 0.99 (0.84-1.18) | 0.944 | 0.96 (0.79-1.17) | 0.706 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CC | 90 (7.88) | 87 (7.42) | 1.07 (0.78-1.46) | 0.695 | 1.10 (0.77-1.58) | 0.591 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dominant | 535 (46.85) | 548 (46.72) | 0.950 | 1.01 (0.85-1.18) | 0.950 | 0.98 (0.82-1.19) | 0.869 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additive model | 0.913 | 1.02 (0.89-1.15) | 0.822 | 1.01 (0.87-1.17) | 0.891 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recessive | 1052 (92.12) | 1086 (92.58) | 0.674 | 1.07 (0.79-1.45) | 0.675 | 1.12 (0.79-1.59) | 0.521 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| rs873601 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GG | 311 (27.23) | 323 (27.54) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AG | 557 (48.77) | 598 (50.98) | 0.97 (0.80-1.17) | 0.738 | 0.97 (0.78-1.21) | 0.796 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AA | 274 (23.99) | 252 (21.48) | 1.13 (0.90-1.42) | 0.303 | 1.11 (0.85-1.44) | 0.448 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dominant | 831 (72.77) | 850 (72.46) | 0.870 | 1.02 (0.85-1.22) | 0.870 | 1.01 (0.82-1.25) | 0.909 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additive model | 0.335 | 1.06 (0.94-1.19) | 0.338 | 1.05 (0.92-1.20) | 0.480 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recessive | 868 (76.01) | 921 (78.52) | 0.150 | 1.15 (0.95-1.40) | 0.150 | 1.13 (0.91-1.41) | 0.286 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Risk genotypes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 0 | 158 (13.84) | 184 (15.69) | 0.185 | 1.00 | 1.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1 | 613 (53.68) | 638 (54.39) | 1.12 (0.88-1.42) | 0.358 | 1.16 (0.88-1.52) | 0.295 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 194 (16.99) | 208 (17.73) | 1.09 (0.81-1.45) | 0.575 | 1.13 (0.81-1.57) | 0.471 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | 176 (15.41) | 142 (12.11) | 1.44 (1.06-1.96) | 0.019 | 1.45 (1.02-2.05) | 0.038 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | 1 (0.09) | 1 (0.09) | 1.17 (0.07-18.77) | 0.915 | 2.61 (0.06-107.90) | 0.614 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 0-2 | 965 (84.50) | 1030 (87.81) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3-4 | 177 (15.50) | 143 (12.19) | 0.021 | 1.32 (1.04-1.68) | 0.021 | 1.29 (0.99-1.69) | 0.062 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CI, confidence interval; OR, odds ratio. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| a Chi square test for genotype distributions between cases and controls. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| b Adjusted for age, gender, pack-years, smoking and drinking status in logistic regress models. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stratification analysis
In the stratified analysis by age, gender, smoking status, pack-year, drinking status, tumor sites and TNM stage, we further evaluated the effects of all the five SNPs and provided the results for rs751402 C>T, rs873601 G>A polymorphisms. The effects of combined risk genotypes on gastric cancer risk were also shown. We failed to find any significant association with gastric cancer risk for any studied variants among subgroups (Table 2). When the risk genotypes were combined, the significant associations with 3-4 risk genotypes were observed in individuals older than 58 years (adjusted OR=1.90, 95% CI=1.06-3.41, P=0.030) and men (adjusted OR=1.50, 95% CI=1.07-2.11, P=0.019), when compared to 0-2 risk genotypes.
Table 2. Stratification analysis for associations between the three XPG variant genotypes and gastric cancer risk in Chinese population.
| Variables | rs751402 (cases/controls) | Adjusted OR (95% CI) | Pa | rs873601 (cases/controls) | Adjusted OR (95% CI) | Pa | Risk genotype (case/control) | Adjusted OR (95% CI) | Pa | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CC/CT | TT | GG/AG | AA | 0-2 | 3-4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Median age, yr | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≤58 | 508/850 | 90/166 | 0.89 (0.67-1.20) | 0.454 | 448/796 | 150/220 | 1.19 (0.93-1.53) | 0.163 | 511/888 | 87/128 | 1.14 (0.84-1.55) | 0.407 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| >58 | 473/134 | 71/23 | 0.82 (0.49-1.36) | 0.436 | 420/125 | 124/32 | 1.12 (0.72-1.75) | 0.604 | 454/142 | 90/15 | 1.90 (1.06-3.41) | 0.030 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gender | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Males | 637/655 | 112/134 | 0.84 (0.61-1.15) | 0.264 | 567/625 | 182/164 | 1.17 (0.89-1.55) | 0.267 | 629/695 | 120/94 | 1.50 (1.07-2.11) | 0.019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Females | 344/329 | 49/55 | 0.83 (0.53-1.31) | 0.431 | 301/296 | 92/88 | 1.07 (0.74-1.55) | 0.708 | 336/335 | 57/49 | 0.98 (0.63-1.54) | 0.940 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Smoking status | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Never | 633/559 | 102/103 | 0.77 (0.55-1.08) | 0.131 | 555/521 | 180/141 | 1.27 (0.94-1.68) | 0.123 | 616/582 | 119/80 | 1.28 (0.90-1.82) | 0.167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ever | 348/425 | 59/86 | 0.89 (0.60-1.34) | 0.590 | 313/400 | 94/111 | 0.98 (0.68-1.40) | 0.896 | 349/448 | 58/63 | 1.24 (0.80-1.92) | 0.330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pack-year | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 0 | 633/559 | 102/103 | 0.77 (0.55-1.08) | 0.131 | 555/521 | 180/141 | 1.27 (0.94-1.68) | 0.123 | 616/582 | 119/80 | 1.28 (0.90-1.82) | 0.167 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≤ 30 | 231/322 | 41/61 | 1.04 (0.63-1.71) | 0.891 | 211/295 | 61/88 | 0.93 (0.60-1.44) | 0.750 | 232/331 | 40/52 | 1.04 (0.62-1.75) | 0.894 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| > 30 | 117/103 | 18/25 | 0.70 (0.35-1.41) | 0.313 | 102/105 | 33/23 | 1.06 (0.56-2.03) | 0.857 | 117/117 | 18/11 | 1.73 (0.73-4.09) | 0.211 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drinking status | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Never | 795/499 | 139/101 | 0.84 (0.62-1.13) | 0.237 | 708/470 | 226/130 | 1.16 (0.89-1.50) | 0.280 | 790/522 | 144/78 | 1.17 (0.85-1.61) | 0.326 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ever | 186/485 | 22/88 | 0.77 (0.44-1.35) | 0.357 | 160/451 | 48/122 | 1.11 (0.71-1.74) | 0.659 | 175/508 | 33/65 | 1.46 (0.85-2.50) | 0.169 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumor site | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cardia | 205/984 | 35/189 | 0.88 (0.57-1.36) | 0.554 | 185/921 | 55/252 | 1.14 (0.78-1.66) | 0.500 | 205/1030 | 35/143 | 1.39 (0.88-2.18) | 0.156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-cardia | 776/984 | 126/189 | 0.81 (0.62-1.07) | 0.141 | 683/921 | 219/252 | 1.14 (0.90-1.43) | 0.279 | 760/1030 | 142/143 | 1.31 (0.99-1.74) | 0.059 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Duke stage | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| I/II | 405/984 | 64/189 | 0.75 (0.53-1.06) | 0.106 | 360/921 | 109/252 | 1.13 (0.85-1.51) | 0.407 | 397/1030 | 72/143 | 1.31 (0.92-1.86) | 0.130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| III/IV | 576/984 | 97/189 | 0.88 (0.65-1.18) | 0.397 | 508/921 | 165/252 | 1.16 (0.90-1.48) | 0.261 | 568/1030 | 105/143 | 1.33 (0.98-1.81) | 0.066 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CI, confidence interval; OR, odds ratio. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| a Obtained in logistic regression models with adjustment for age, gender, pack-years, smoking and drinking status with omitting the corresponding stratification factor. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haplotype analysis
The frequency of inferred haplotypes of XPG gene based on observed genotypes and their association with the risk of gastric cancer were shown in Table 3. None of the haplotype was associated with gastric cancer risk significantly.
Table 3. The frequency of inferred haplotypes of XPG gene based on observed genotypes and their association with the risk of gastric cancer.
| Haplotypes a | Cases (n=2284) | Controls (n=2346) | Crude OR (95% CI) | P | Adjusted OR b (95% CI) | Pb | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CTTTG | 747 (32.71) | 802 (34.19) | 1.00 | 1.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CTTTA | 123 (5.39) | 122 (5.20) | 1.08 (0.83-1.42) | 0.565 | 1.06 (0.78-1.44) | 0.694 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CTTCG | 4 (0.18) | 5 (0.21) | 0.86 (0.23-3.21) | 0.821 | 0.64 (0.15-2.75) | 0.547 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CTTCA | 1 (0.04) | 0 | / | 0.978 | / | 0.981 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CTCTA | 1 (0.04) | 0 | / | 0.978 | / | 0.980 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCTTG | 140 (6.13) | 150 (6.39) | 1.00 (0.78-1.29) | 0.987 | 0.92 (0.70-1.23) | 0.584 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCTTA | 67 (2.93) | 80 (3.41) | 0.90 (0.64-1.26) | 0.540 | 0.80 (0.54-1.18) | 0.253 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCTCG | 31 (1.36) | 48 (2.05) | 0.69 (0.44-1.10) | 0.121 | 0.82 (0.49-1.40) | 0.468 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCTCA | 73 (3.20) | 66 (2.81) | 1.19 (0.84-1.68) | 0.332 | 1.17 (0.79-1.72) | 0.443 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCCTG | 5 (0.22) | 8 (0.34) | 0.67 (0.22-2.06) | 0.486 | 0.76 (0.21-2.76) | 0.679 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCCTA | 2 (0.09) | 2 (0.09) | 1.07 (0.15-7.64) | 0.943 | 1.58 (0.19-13.31) | 0.674 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCCCG | 194 (8.49) | 177 (7.54) | 1.18 (0.94-1.48) | 0.160 | 1.14 (0.88-1.47) | 0.330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CCCCA | 118 (5.17) | 118 (5.03) | 1.07 (0.82-1.41) | 0.611 | 1.16 (0.85-1.58) | 0.358 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TTTTG | 1 (0.04) | 0 | / | 0.978 | / | 0.976 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCTTG | 40 (1.75) | 43 (1.83) | 1.00 (0.64-1.55) | 0.996 | 1.02 (0.62-1.68) | 0.925 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCTTA | 528 (23.12) | 498 (21.23) | 1.14 (0.97-1.33) | 0.108 | 1.13 (0.95-1.36) | 0.169 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCTCG | 6 (0.26) | 2 (0.09) | 3.22 (0.65-16.01) | 0.153 | 2.10 (0.40-11.05) | 0.383 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCTCA | 53 (2.32) | 64 (2.73) | 0.89 (0.61-1.30) | 0.542 | 0.87 (0.57-1.34) | 0.538 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCCTA | 5 (0.22) | 6 (0.26) | 0.90 (0.27-2.94) | 0.855 | 1.07 (0.30-3.83) | 0.918 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCCCG | 11 (0.48) | 9 (0.38) | 1.31 (0.54-3.18) | 0.548 | 1.41 (0.51-3.91) | 0.504 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TCCCA | 134 (5.87) | 146 (6.22) | 0.99 (0.76-1.27) | 0.910 | 0.89 (0.66-1.18) | 0.411 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| a The haplotypes order were rs2094258, rs751402, rs2296147, rs1047768, and rs873601. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| b Obtained in logistic regression models with adjustment for age, gender, pack-years, smoking and drinking status. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discussion
In the present study, we investigated the impact of five potentially functional XPG SNPs on gastric cancer risk in a Chinese Han population from South China. Our analysis indicated that none of these SNPs could individually influence the gastric cancer susceptibility. However, the individuals carrying 3-4 risk genotypes had a significantly increased gastric cancer risk, especially among those older than 58 years and men. To the best of our knowledge, this is the largest study to investigate the association of these five XPG polymorphisms with the gastric cancer risk by far.
XPG is an indispensable component of the NER pathway, which is responsible for the cleavage of DNA on the 3’ side of lesion and also recruit PCNA to the damage sites for the subsequent gap-filling DNA synthesis in mammals [31]. It is reported that XPG also participates in other cellular processes, such as transcription-coupled DNA repair and RNA polymerase II transcription [32,33].
Recently, several studies have been carried out to explore the role of XPG polymorphisms in gastric cancer susceptibility; however, inconsistent results have been reported. We previously evaluated the association between XPG (rs2094258 C>T, rs2296147 T>C and rs873601 G>A) and gastric cancer risk in an Eastern Chinese population with 1125 cases and 1196 controls. We found that the rs873601 G>A polymorphism (located in the 3’ UTR) was significantly associated with an increased gastric cancer risk [22]. We also demonstrated that rs873601 A allele was significantly associated with reduced mRNA expression level of XPG gene. These three polymorphisms were also genotyped in 337 gastric cancer cases and 347 controls by Yang and coworkers [24]. Intriguingly, they found that the rs2296147 T>C polymorphism was associated with a decreased gastric cancer risk, while the rs2094258 C>T polymorphism was associated with an increased gastric cancer risk [24]. In a study by Duan et al. [21], composed of 400 gastric cancer cases and 400 healthy controls, both rs751402 C>T and rs2296147 T>C polymorphisms were shown to significantly increase gastric cancer risk. Recently, Chen et al. [23] explored the association of rs2094258 C>T, rs751402 C>T, rs2296147 T>C and rs873601 G>A polymorphisms with gastric cancer susceptibility in 692 cases and 771 healthy controls. However, only XPG rs873601 G>A polymorphism appeared to be associated with the risk of gastric cancer. This controversy regarding the association might be partly due to ethnic and demographic differences, or insufficient statistical power caused by small sample size.
With this in mind, we conducted the current study with 1142 cases and 1173 controls. We found no significant association between variant genotypes of XPG polymorphisms and gastric cancer risk. However, the individuals carrying 3-4 risk genotypes were at significantly increased gastric cancer risk, especially for individuals older than 58 years and men. Overall, the negative results might be partially ascribed to the mild effect of each variant. In addition, the moderate sample size in this study might not be large enough to detect relatively weak association. Besides, complex interactions between environmental and genetic factors should be taken into account while measuring the true associations of XPG gene polymorphisms with gastric cancer.
Despite that this is the largest study to extensively analyze the association of five potentially functional XPG polymorphisms with gastric cancer in a Southern Chinese population, there still exists some limitations. First, frequency matching between cases and controls in this research were only performed on gender, but not on age, smoking and drinking status. We used multivariate logistic regression analysis to minimize the impact of these confounding factors, to some extent. Second, gastric cancer is a heterogeneous disease which might be influenced by other related factors such as H. pylori infection, diet, occupational exposure, and environmental factors. Since such information on participants was missing, the results should be explained with caution. Third, due to the hospital-based case-control design, our study was inevitably suffered from the selection bias. Moreover, the conclusions drawn from subjects residing in South China may not well represent other Chinese populations in the different regions. Fourth, only five potentially functional SNPs were included in this study. As a result, SNPs from the coding and the intron regions that may also be related to gastric cancer risk could be omitted. Finally, we only investigated the association between XPG gene polymorphisms and gastric cancer risk. Genetic variations in other genes (e.g. KDM5A, DNAH7 [34], PLCE1 [35], PSCA [36,37], PRKAA1 [38], MUC1 [39]) reported to be specifically associated with gastric cancer initiation and progression were not investigated in the current study.
In conclusion, we found that none of the XPG rs2094258 C>T, rs751402 C>T, rs2296147 T>C, rs1047768 T>C and rs873601 G>A polymorphisms was associated with gastric cancer susceptibility. However, cumulative effects of risk genotypes (3-4) on the risk of gastric cancer were observed. Further well-designed, prospective studies with large-scale multicenter investigations involving different ethnicities are required to verify our conclusions.
Materials and Methods
Study subjects
The study protocol was approved by the institutional review board of Sun Yat-sen University Cancer Center. All participants of this study signed individual informed consent. This study consisted of 1142 patients and 1173 healthy controls as we describe previously [40]. All subjects were unrelated ethnic Han Chinese population from Southern China, mainly from Guangdong, Guangxi, and Hainan province. In general, the response rate of cases and controls was more than 85%.
SNP selection and genotyping
Five potentially functional SNPs in the XPG gene were selected for this study as we described previously [28,29]. Briefly, we searched the potentially functional candidate SNPs located in the 5’- flanking region, exon, 5’ UTR, and 3’ UTR, which might affect transcription activity and the microRNA binding site activity. As predicted by SNPinfo software (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html), five SNPs (rs2094258 C>T, rs751402 C>T, rs2296147 T>C, rs1047768 T>C and rs873601 G>A) were potentially functional (Supplemental Table S2). All these SNPs have a minor allele frequency no less than 5% for Chinese Han subjects. There is no significant linkage disequilibrium (LD) (R2<0.8) among these SNPs. DNA samples were genotyped by the Taqman real-time PCR method as we described previously [22,41].
Statistical analysis
Goodness-of-fit χ2 test was used to check whether genotype frequency distribution of each polymorphism in controls were in accordance with HWE. We compared the differences in demographic variables as well as genotype frequencies between cases and controls by using the two-sided χ2 test. ORs and 95% CIs were used to estimate the effect of SNPs and haplotypes on gastric cancer risk. Adjusted ORs were calculated by unconditional multivariate logistic regression analysis, with adjustment for age, gender, pack-years, smoking and drinking status. We determined the risk genotypes for each SNP based on its association with gastric cancer susceptibility. If a genotype of a SNP was shown to increase gastric cancer risk (OR>1), the genotype was regarded as a risk genotype. For example, as to the rs2094258 C>T polymorphism, ORs of 1.02 (heterozygous model) and 1.17 (homozygous model) indicated that the T allele carriers (CT/TT) may have an increased risk when compared to those with CC genotypes (Table 1). Thus, the CC wild-type genotype carriers was define as 0, while the CT or TT genotype carriers was defined as 1. We then divided subjects into two groups based the number of risk genotypes. Carriers of 3-4 risk genotypes represented those carrying 3-4 risk genotypes of the five SNPs, while 0-2 risk genotypes represented those carrying 0-2 risk genotypes. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC). A P value of <0.05 was considered as statistically significant.
Supplementary Materials
Supplemental File
Conflicts of Interest
The authors declare no competing financial interests.
Funding
This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81502046), Special Financial Grant from the China Postdoctoral Science Foundation (Grant No. 2014T70836), the Natural Science Foundation of Guangdong Province (Grant No. 2015A030310324), and the National Science Fund for Distinguished Young Scholars (Grant No. 81325018).
References
- 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. https://doi.org/10.1002/ijc.29210 [PubMed]
- 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87–108. https://doi.org/10.3322/caac.21262 [PubMed]
- 3. Amedei A, Benagiano M, della Bella C, Niccolai E, D’Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011; 2011:437348. 10.1155/2011/437348.
- 4. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol. 2010; 25:479–86. https://doi.org/10.1111/j.1440-1746.2009.06188.x [PubMed]
- 5. van Blankenstein M, van Vuuren AJ, Looman CW, Ouwendijk M, Kuipers EJ. The prevalence of Helicobacter pylori infection in the Netherlands. Scand J Gastroenterol. 2013; 48:794–800. https://doi.org/10.3109/00365521.2013.799221 [PubMed]
- 6. Moayyedi P, Axon AT, Feltbower R, Duffett S, Crocombe W, Braunholtz D, Richards ID, Dowell AC, Forman D, Leeds HS, and Leeds HELP Study Group. Relation of adult lifestyle and socioeconomic factors to the prevalence of Helicobacter pylori infection. Int J Epidemiol. 2002; 31:624–31. https://doi.org/10.1093/ije/31.3.624 [PubMed]
- 7. Pelucchi C, Tramacere I, Bertuccio P, Tavani A, Negri E, La Vecchia C. Dietary intake of selected micronutrients and gastric cancer risk: an Italian case-control study. Ann Oncol. 2009; 20:160–65. https://doi.org/10.1093/annonc/mdn536 [PubMed]
- 8. Zabaleta J. Multifactorial etiology of gastric cancer. Methods Mol Biol. 2012; 863:411–35. https://doi.org/10.1007/978-1-61779-612-8_26 [PubMed]
- 9. Mocellin S, Verdi D, Pooley KA, Nitti D. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut. 2015; 64:1209–19. https://doi.org/10.1136/gutjnl-2015-309168 [PubMed]
- 10. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001; 291:1284–89. https://doi.org/10.1126/science.1056154 [PubMed]
- 11. Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M, Debinskie W, Zhao W, Chan MD, Zhou X. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.10553 [PubMed]
- 12. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med. 2003; 3:589–96. https://doi.org/10.2174/1566524033479456 [PubMed]
- 13. Gillet LC, Schärer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev. 2006; 106:253–76. https://doi.org/10.1021/cr040483f [PubMed]
- 14. Cordonnier AM, Fuchs RP. Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. Mutat Res. 1999; 435:111–19. https://doi.org/10.1016/S0921-8777(99)00047-6 [PubMed]
- 15. Cleaver JE. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci. 2000; 23:1–11. https://doi.org/10.1016/S0923-1811(99)00088-2 [PubMed]
- 16. Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG. Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature. 1993; 363:182–85. https://doi.org/10.1038/363182a0 [PubMed]
- 17. Sugasawa K. Xeroderma pigmentosum genes: functions inside and outside DNA repair. Carcinogenesis. 2008; 29:455–65. https://doi.org/10.1093/carcin/bgm282 [PubMed]
- 18. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem. 1997; 272:16030–34. https://doi.org/10.1074/jbc.272.25.16030 [PubMed]
- 19. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer. 2009; 65:230–36. https://doi.org/10.1016/j.lungcan.2008.11.014 [PubMed]
- 20. Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer. 2012; 76:354–61. https://doi.org/10.1016/j.lungcan.2011.12.002 [PubMed]
- 21. Duan WX, Hua RX, Yi W, Shen LJ, Jin ZX, Zhao YH, Yi DH, Chen WS, Yu SQ. The association between OGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis of 27 studies. PLoS One. 2012; 7:e35970. https://doi.org/10.1371/journal.pone.0035970 [PubMed]
- 22. He J, Qiu LX, Wang MY, Hua RX, Zhang RX, Yu HP, Wang YN, Sun MH, Zhou XY, Yang YJ, Wang JC, Jin L, Wei QY, Li J. Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet. 2012; 131:1235–44. https://doi.org/10.1007/s00439-012-1152-8 [PubMed]
- 23. Chen YZ, Guo F, Sun HW, Kong HR, Dai SJ, Huang SH, Zhu WW, Yang WJ, Zhou MT. Association between XPG polymorphisms and stomach cancer susceptibility in a Chinese population. J Cell Mol Med. 2016; 20:903–08. https://doi.org/10.1111/jcmm.12773 [PubMed]
- 24. Yang WG, Zhang SF, Chen JW, Li L, Wang WP, Zhang XF. SNPs of excision repair cross complementing group 5 and gastric cancer risk in Chinese populations. Asian Pac J Cancer Prev. 2012; 13:6269–72. https://doi.org/10.7314/APJCP.2012.13.12.6269 [PubMed]
- 25. Zhu ML, Shi TY, Hu HC, He J, Wang M, Jin L, Yang YJ, Wang JC, Sun MH, Chen H, Zhao KL, Zhang Z, Chen HQ, et al. Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations. PLoS One. 2012; 7:e41500. https://doi.org/10.1371/journal.pone.0041500 [PubMed]
- 26. Du H, Zhang X, Du M, Guo N, Chen Z, Shu Y, Zhang Z, Wang M, Zhu L. Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population. Sci Rep. 2014; 4:6700. https://doi.org/10.1038/srep06700 [PubMed]
- 27. Wang F, Zhang SD, Xu HM, Zhu JH, Hua RX, Xue WQ, Li XZ, Wang TM, He J, Jia WH. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer. Oncotarget. 2016; 7:11724–32. https://doi.org/10.18632/oncotarget.7352 [PubMed]
- 28. Hua RX, Zhuo ZJ, Zhu J, Zhang SD, Xue WQ, Zhang JB, Xu HM, Li XZ, Zhang PF, He J, Jia WH. XPG gene polymorphisms contribute to colorectal cancer susceptibility: a two-stage case-control study. J Cancer. 2016; 7:1731–39. https://doi.org/10.7150/jca.15602 [PubMed]
- 29. He J, Wang F, Zhu J, Zhang R, Yang T, Zou Y, Xia H. Association of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese population. J Cell Mol Med. 2016; 20:1481–90. https://doi.org/10.1111/jcmm.12836 [PubMed]
- 30. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010; 17(12):3077-3079.
- 31. Schärer OD. XPG: its products and biological roles. Adv Exp Med Biol. 2008; 637:83–92. https://doi.org/10.1007/978-0-387-09599-8_9 [PubMed]
- 32. Hanawalt PC. Transcription-coupled repair and human disease. Science. 1994; 266:1957–58. https://doi.org/10.1126/science.7801121 [PubMed]
- 33. Lee SK, Yu SL, Prakash L, Prakash S. Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase II transcription. implications for Cockayne syndrome. Cell. 2002; 109:823–34. https://doi.org/10.1016/S0092-8674(02)00795-X [PubMed]
- 34. Tan H, Bao J, Zhou X. Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Sci Rep. 2015; 5:12566. https://doi.org/10.1038/srep12566 [PubMed]
- 35. Xue W, Zhu M, Wang Y, He J, Zheng L. Association between PLCE1 rs2274223 A > G polymorphism and cancer risk: proof from a meta-analysis. Sci Rep. 2015; 5:7986. https://doi.org/10.1038/srep07986 [PubMed]
- 36. Gu Y, Dai QS, Hua RX, Zhang B, Zhu JH, Huang JW, Xie BH, Xiong SQ, Tan GS, Li HP. PSCA s2294008 C>T and rs2976392 G>A polymorphisms contribute to cancer susceptibility: evidence from published studies. Genes Cancer. 2015; 6:254–64. https://doi.org/10.18632/genesandcancer.63 [PubMed]
- 37. Qiu LX, Cheng L, He J, Zhou ZR, Wang MY, Zhou F, Guo WJ, Li J, Sun MH, Zhou XY, Wang YN, Yang YJ, Wang JC, et al. PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population. Oncotarget. 2016; 7:9420–28. https://doi.org/10.18632/oncotarget.7137 [PubMed]
- 38. Qiu LX, He J, Cheng L, Zhou F, Wang MY, Sun MH, Zhou XY, Li J, Guo WJ, Wang YN, Yang YJ, Wang JC, Jin L, et al. Genetic variant of PRKAA1 and gastric cancer risk in an eastern Chinese population. Oncotarget. 2015; 6:42661–66. https://doi.org/10.18632/oncotarget.6124 [PubMed]
- 39. Qiu LX, Hua RX, Cheng L, He J, Wang MY, Zhou F, Zhu XD, Sun MH, Zhou XY, Li J, Wang YN, Yang YJ, Wang JC, et al. Genetic variant rs4072037 of MUC1 and gastric cancer risk in an Eastern Chinese population. Oncotarget. 2016; 7:15930–36. https://doi.org/10.18632/oncotarget.7527 [PubMed]
- 40. Hua RX, Zhuo ZJ, Shen GP, Zhu J, Zhang SD, Xue WQ, Li XZ, Zhang PF, He J, Jia WH. Polymorphisms in the XPC gene and gastric cancer susceptibility in a Southern Chinese population. Onco Targets Ther. 2016; 9:5513–19. https://doi.org/10.2147/OTT.S113055 [PubMed]
- 41. He J, Zhang R, Zou Y, Zhu J, Yang T, Wang F, Xia H. Evaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese population. Tumour Biol. 2016; 37:1635–39. https://doi.org/10.1007/s13277-015-3936-7 [PubMed]